[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100484176":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":60,"collaborators":39,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":39,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":39,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":84,"overallStatus":44,"whyStopped":39,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Rutgers, The State University of New Jersey","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intravenous immune globulin G","EXPERIMENTAL","Subjects will receive there current intravenous immune globulin dose.",[13],"Drug: Intravenous immune globulin G",{"label":15,"type":10,"description":16,"interventionNames":17},"Subcutaneous immune globulin G","The dosage will be converted from the subject's current intravenous immune globulin G dosage 1:1 (gm per gm).",[18],"Drug: Subcutaneous immune globulin G",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Intravenous immune globulin G dosed based on the subjects's current dose received for the treatment of CIDP.",[9],[25],"Privigen, IVIG",{"type":21,"name":15,"description":27,"armGroupLabels":28,"otherNames":29},"Subcutaneous immune globulin G converted from the subject's current IVIG dose 1:1.",[15],[30],"Hizentra, SCIG",[32],{"name":33,"affiliation":5,"role":34},"Luigi Brunetti, PhD","PRINCIPAL_INVESTIGATOR",[36],{"name":33,"role":37,"phone":38,"phoneExt":39,"email":40},"CONTACT","2016385868",null,"brunetti@pharmacy.rutgers.edu",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"Rutgers, The State University of New Jersey Clinical Research Center","RECRUITING","New Brunswick","New Jersey","08901","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-74.45182,40.48622,{"lat":54,"lon":53},[57],{"name":33,"role":37,"phone":58,"phoneExt":39,"email":59},"9085952645","luigi.brunetti@rutgers.edu",{"type":34,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":39,"oldOrganization":39},"Luigi Brunetti","Associate Professor","100484176","phase-1-ivig-vs-scig-in-cidp-100484176",false,"NCT05584631","IVIG vs SCIG in CIDP","The Influence of Body Composition on Immunoglobulin Disposition After Intravenous and Subcutaneous Administration","Inclusion Criteria:\n\n* Patients aged \\>18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences \u002F Peripheral Nerve Society CIDP diagnostic criteria).\n* 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg\u002Fkg dose for SCIG.\n\nExclusion Criteria:\n\n* Patients receiving IVIG for indications other than CIDP will be excluded.\n* Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl \\\u003C 50 mL\u002Fmin) will be excluded\n* Active malignancies\n* Diabetes\n* Myasthenia gravis\n* Immunodeficiency\n* Autoimmune disease","ALL","18 Years","65 Years",{"count":74,"type":75},20,"ESTIMATED","INTERVENTIONAL",[78],"PHASE1","Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.",[81,82,83],"CIDP","Immunoglobulin Deficiency","Chronic Inflammatory Demyelinating Polyneuropathy",[85,86,87],"immunoglobulin","pharmacokinetics","obesity","2025-12-10",{"date":90,"type":91},"2025-12-11","ACTUAL",{"date":93,"type":91},"2022-09-11",{"date":95,"type":75},"2026-12-01",{"name":5,"class":6},1]